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A B S T R A C T
Prader-Willi syndrome (PWS) is the most common genetic obesity syndrome, with associated learning diffi-
culties, neuroendocrine deficits, and behavioural and psychiatric problems. As the life expectancy of individuals
with PWS increases, there is concern that alterations in brain structure associated with the syndrome, as a direct
result of absent expression of PWS genes, and its metabolic complications and hormonal deficits, might cause
early onset of physiological and brain aging.
In this study, a machine learning approach was used to predict brain age based on grey matter (GM) and
white matter (WM) maps derived from structural neuroimaging data using T1-weighted magnetic resonance
imaging (MRI) scans. Brain-predicted age difference (brain-PAD) scores, calculated as the difference between
chronological age and brain-predicted age, are designed to reflect deviations from healthy brain aging, with
higher brain-PAD scores indicating premature aging.
Two separate adult cohorts underwent brain-predicted age calculation. The main cohort consisted of adults with
PWS (n=20; age mean 23.1 years, range 19.8–27.7; 70.0% male; body mass index (BMI) mean 30.1 kg/m2,
21.5–47.7; n=19 paternal chromosome 15q11–13 deletion) and age- and sex-matched controls (n=40; age
22.9 years, 19.6–29.0; 65.0% male; BMI 24.1 kg/m2, 19.2–34.2) adults (BMI PWS vs. control P=.002). Brain-PAD
was significantly greater in PWS than controls (effect size mean ± SEM+7.24 ± 2.20 years [95% CI 2.83, 11.63],
P= .002). Brain-PAD remained significantly greater in PWS than controls when restricting analysis to a sub-cohort
matched for BMI consisting of n=15 with PWS with BMI range 21.5–33.7 kg/m2, and n=29 controls with BMI
21.7–34.2 kg/m2 (effect size +5.51 ± 2.56 years [95% CI 3.44, 10.38], P=.037). In the PWS group, brain-PAD
scores were not associated with intelligence quotient (IQ), use of hormonal and psychotropic medications, nor se-
verity of repetitive or disruptive behaviours. A 24.5 year old man (BMI 36.9 kg/m2) with PWS from a SNORD116
microdeletion also had increased brain PAD of 12.87 years, compared to 0.84 ± 6.52 years in a second control adult
cohort (n=95; age mean 34.0 years, range 19.9–55.5; 38.9% male; BMI 28.7 kg/m2, 19.1–43.1).
This increase in brain-PAD in adults with PWS indicates abnormal brain structure that may reflect premature
brain aging or abnormal brain development. The similar finding in a rare patient with a SNORD116 micro-
deletion implicates a potential causative role for this PWS region gene cluster in the structural brain abnorm-
alities associated primarily with the syndrome and/or its complications. Further longitudinal neuroimaging
studies are needed to clarify the natural history of this increase in brain age in PWS, its relationship with obesity,
and whether similar findings are seen in those with PWS from maternal uniparental disomy.
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1. Introduction
Prader-Willi Syndrome (PWS) is a multi-system, genetically de-
termined, neurodevelopmental disorder arising from the loss of ex-
pression of genes of paternal inheritance on chromosome 15 (Bittel and
Butler, 2005). PWS results from a paternal deletion of chromosome
15q11-q13 in 75% of cases (Amos-Landgraf et al., 1999), maternal
uniparental disomy (mUPD) in 24%, and genetic imprinting errors in
1% of cases (Horsthemke and Buiting, 2006; Goldstone et al., 2008).
PWS has an estimated birth incidence of 1 in 27,000 individuals and
presents with a characteristic but variable phenotype affecting many
organ systems (Whittington et al., 2001; Gunay-Aygun et al., 2001;
Smith et al., 2003). PWS is characterised by its nutritional phases from
initial feeding difficulties and failure-to-thrive in infancy, to progressive
hyperphagia and morbid obesity (if access to food is not controlled)
from later childhood to adulthood, growth hormone (GH) and sex
hormone deficiencies, secondary to hypothalamic dysfunction (Miller
et al., 2007; Goldstone et al., 2008; Goldstone et al., 2012), and possible
pro-hormone/−neuropeptide precursor processing defects (Burnett
et al., 2017). PWS is also associated with developmental delay, mild to
moderate intellectual disability, and behavioural and psychiatric dis-
turbances (Cassidy and Driscoll, 2009).
In the past, mortality rates for people with intellectual disabilities
was higher than it is now (Maaskant et al., 2002), and in recent years,
the life expectancy of people with PWS has increased, thanks to im-
provements in clinical management (Whittington et al., 2015). How-
ever, increased morbidity and secondary complications, such as re-
spiratory infections and cardiorespiratory failure related to obesity,
continue to be the major cause of death in individuals with PWS
(Schrander-Stumpel et al., 2004; Vogels et al., 2004). Reports of older
people with PWS are scarce, as most research has focused on clinical
characteristics of PWS in childhood, adolescence and early adulthood
(Sinnema et al., 2012).
People with PWS have abnormal development in certain brain areas
(Manning and Holland, 2015), with some structural differences de-
pending on their genetic subtypes and varying between early atrophy
and arrested development (Lukoshe et al., 2013). Two main competing
hypotheses may explain the neurological and behavioural changes as-
sociated with PWS:
1. Premature aging and brain atrophy. Reports from older PWS pa-
tients describe cases of cortical atrophy and signs of premature aging,
similar to that seen in other neurodegenerative diseases (Sinnema et al.,
2012), cognitive and functional decline affecting language, memory,
orientation, and behaviour, with higher incidence in women (Maaskant
et al., 2002; Whittington et al., 2015;), and cases meeting criteria of
Alzheimer-type dementia (Sinnema et al., 2010; Whittington et al.,
2015).
2. Atypical and arrested development. Arrested development in PWS
might explain some core phenotypes such as repetitive behaviour and
tantrums (Holland et al., 2003). Some neuroimaging findings also in-
dicate a fundamental arrest in brain development in children with PWS,
or a divergence from the normal developmental pattern (Lukoshe et al.,
2013).
Given the uncertainties of brain development and aging in PWS, a
better understanding of neurological abnormalities and age-related
changes in the brain in comparison to typical development is needed to
allow better prediction of health outcomes and to provide insights into
the role of parental-origin specific genomic imprinting from a devel-
opmental and evolutionary point of view.
Study of rare mutations or microdeletions of specific PWS genes can
also reveal much about genotype-phenotype associations in PWS.
Recent rare case reports have revealed that smaller deletions of some
genes on chromosome 15q11–13 can lead to features associated with
PWS, even in the absence of the full diagnostic criteria for PWS, in-
cluding a ~187 kb microdeletion encompassing several small nucleolar
RNAs (snoRNAs) gene clusters, especially the SNORD116 cluster. The
phenotype of such cases includes hyperphagia, severe obesity, learning
difficulties and hypogonadism (Sahoo et al., 2008; de Smith et al.,
2009; Duker et al., 2010; Bieth et al., 2015).
To evaluate age-related changes to brain structure, neuroimaging
data has been used to predict chronological age based on a multivariate
machine-learning model of healthy individuals (Franke et al., 2010;
Cole et al., 2018). Using this paradigm, both genetic and environmental
factors have been reported to influence brain aging. These include
obesity and type 2 diabetes mellitus (T2DM) (Franke et al., 2013; Ronan
et al., 2016), HIV disease (Cole et al., 2017b), and certain neu-
ropsychiatric disorders (Gaser et al., 2013; Koutsouleris et al., 2014;
Schnack et al., 2016), which cause the brain to appear older than it
actually is chronologically. Meanwhile, neuroprotective factors, such as
physical exercise and higher cognitive reserve, have been associated
with slower brain aging (Luders et al., 2016; Steffener et al., 2016).
Recently, this model was used to show that genetic Down syndrome
(trisomy of chromosome 21) is associated with early onset of structural
brain changes corresponding to premature brain aging (Cole et al.,
2017a). The deviation from the normal trend of brain maturation and
aging seems to be an accurate indication of important neurological
changes associated with physiological abnormalities in the elderly, and
indeed is a predictor of mortality (Cole et al., 2018).
In this paper, we investigated brain age in young adults with PWS
compared to healthy individuals, to determine whether they exhibited
patterns of arrested development or premature aging. We also explored
whether brain structural changes were related to common clinical
characteristics of PWS, namely high body mass index (BMI), low in-
tellectual quotient (IQ), hormonal status, psychiatric medication use,
and behavioural measures, to identify possible mechanisms and asso-
ciations with the abnormalities accompanying PWS. We also examined
brain age in one of the rare cases of PWS due to a SNORD116 micro-
deletion to identify potential gene(s) in the PWS chromosomal region
contributing to changes in brain age (de Smith et al., 2009).
2. Subjects and methods
2.1. Participants
2.1.1. Training set
Training sets are typically used in machine learning to discover
relationship patterns that can be applied for future predictions without
explicit input by the researcher. In this case, T1-weighted MRI scans
were collected from public sources (Supplementary Table 1), and in-
cluded 2001 typically developing individuals (1016 males (50.8%), age
mean ± SD 37.0 ± 18.1 years, range 18.0–90.0). The participants
were screened according to their respective study's criteria, to ensure
the absence of psychological or neurological diagnosis, and major
health conditions. The scans were used to derive a statistical model of
healthy brain structure across the lifespan.
2.1.2. Test sets
The model constructed by the training set was then applied for
predictive analysis on the test set. In our study, the test sets comprised
two separate adult cohorts.
2.1.2.1. Cohort 1 - PWS and matched controls. This cohort included
n=20 adults with PWS (mean ± SD age 23.1 ± 2.4 years) and
n=40 age- and sex-matched, typically developing controls (age
22.9 ± 2.2 years) (Table 1). All participants were recruited at the
University of Cambridge to undergo MRI scans. Participants needed to
be between 18 and 28 years old, of either sex and have the capacity to
consent. Written informed consent was given by all participants. All
participants had height and weight recorded. This cohort has previously
been described in (Manning and Holland, 2015). Typically developing
control participants aged 18–24 years (n=36) were recruited and
tested as part of the NeuroScience in Psychiatry Network (NSPN) U-
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Change project, enabling the selection of age and sex-matched controls.
Additional control participants aged 24–28 years (n=4) were recruited
from the local population.
For the PWS group, where genetic diagnosis of subtypes was not
available in medical records, the genotype was confirmed using blood
or saliva samples. Records of medication and hormonal therapies were
given by participants, parents and care-givers. IQ was assessed in the
PWS group using the Wechsler Adult Intelligence Scale Fourth Edition
(WAIS-IV; Pearson, London, UK). For the control group, a shortened
version of the WAIS was used (vocabulary and matrix reasoning subt-
ests) from the Wechsler Abbreviated Scale of Intelligence Second
Edition (WASI-II; Pearson, London, UK). The Developmental Behaviour
Checklist for Adults (DBC-A) was used to assess behaviour difficulties
and temper outbursts in PWS using DBC-A disruptive score (Mohr et al.,
2005). The Repetitive Behaviour Scale - Revised (RBS-R) was used to
measure the severity of repetitive behaviours using RBS-R sameness
score (Bodfish et al., 2000).
Exclusion criteria were: inability to tolerate MRI scans, history of
psychiatric disorder for controls or current psychiatric disorder dis-
rupting compliance with study demands for PWS participants, history
of neurological disease or trauma, currently or recently participating in
a clinical trial for medicinal investigation, metal object precluding MRI,
and currently being treated for drug or alcohol dependency. Ethical
approval for the study was granted by the Cambridge East (East of
England) NHS National Research Ethics Committee (REC number 13/
EE/0373).
2.1.2.2. Cohort 2 - SNORD116 microdeletion and controls. One adult
male of Indian ethnicity with a SNORD116 microdeletion, previously
reported in (de Smith et al., 2009), was recruited from the PWS and
genetic obesity clinic at Hammersmith Hospital, Imperial College
Healthcare NHS trust, London, run by A.P.G., with written informed
consent, for an MRI brain scan (West London 1 REC, number 10/
H0707/60). At the time of imaging he was 24.5 years old with BMI
36.9 kg/m2 (Table 2).
A total of n=95 adults were included in the control group for the
patient with the SNORD116 microdeletion, consisting of n=30 with
BMI<25.0 kg/m2, n=37 with BMI≥25.0 and < 30.0 kg/m2, and
n=28 with BMI≥30.0 (Table 2). All controls had previously taken
part in one of six studies investigating the effects of hormones, obesity
surgery and dietary manipulations on brain activation in functional
MRI studies (REC 07/Q0406/19, 08/Q0707/139, 08/H0707/99, 09/
H0709/18, 09/H0707/30, 10/H0707/60). All subjects gave written
informed consent. Inclusion criteria were BMI between 18.0 and
50.0 kg/m2, age 18–60 years of either sex. Exclusion criteria were
claustrophobia, metal object precluding MRI, inability to read and
understand English, T2DM receiving insulin or GLP-1 receptor agonist
therapy, type 1 diabetes mellitus, current smoker, history of cancer,
epilepsy, cerebrovascular accident, ischaemic heart disease, cardiac
arrhythmia, respiratory disease other than mild asthma, alcohol or
other drug dependence, significant renal, gastrointestinal, hepatic dis-
ease, or endocrine disease other than controlled and treated primary
hypothyroidism, known prematurity (gestation< 32weeks), unstable
depression (dose change of anti-depressants in last 3months). Subjects
on anti-hypertensive, lipid lowering medication or anti-depressant
medication were not excluded.
2.2. Procedure
2.2.1. Neuroimaging data acquisition
For the training set, the acquisition of three-dimensional T1-
weighted MRI scans was conducted using various parameters and field
strengths (either 1.5T or 3T) depending on local study protocols
(Supplementary Table 1).
2.2.1.1. PWS and matched controls. Three-dimensional, high-
resolution, T1-weighted MRI scans for the acquisition of structural
images for the PWS and control groups, used a Siemens 3T scanner
Table 1
Characteristics of Prader-Willi syndrome and controls (cohort 1).
PWS Control P-valuea
n 20 40
Demographic and anthropometric data
Age (y) 22.6 [21.3, 24.8] (19–27) 22.4 [21.3, 24.3] (19–29) 0.74
Male n (%) 14 (70.0%) 26 (65.0%) 0.70
BMI (kg/m2) 30.1 ± 7.2 (21.5–47.7) 24.1 ± 3.8 (19.2–34.2) < 0.001
T2DM n (%) 4 (20.0%) NA NA
Genotype (n) 19 Del, 1 mUPD NA NA
Psychological measurements
IQ 63.1 ± 11.9 (48–95) 112.9 ± 11.2 (81–132) < 0.001
DBC-A disruptive (max 48) 17.6 ± 9.9 (2–43) NA NA
RBS-R - sameness (max 33) 6.8 ± 7.0 (1–24) NA NA
Medications
Growth hormone n (%) Ever 17 (85.0%) 0 NA
Current 7 (35.0%)
Sex hormones n (%) Ever 15 (75.0%) 0 NA
Current 7 (35.0%)
Psychoactive n (%) 10 (50.0%)b 0 NA
Anti-psychotic n (%) 3 (15.0%)b 0 NA
Anti-depressants n (%) 7 (35.0%)b 0 NA
Benzodiazepines n (%) 1 (5.0%)b 0 NA
Anti-convulsant n (%) 1 (5.0%)b 0 NA
Anti-cholinergic n (%) 1 (5.0%)b 0 NA
Diabetes n (%) 3 (15%)b 0 NA
All data given as mean ± SD (range), median [interquartile range] (range), or n (%).
Abbreviations: DBC-A: disruptive behaviour scale, Del: deletion, mUPD: maternal uniparental disomy, NA: not applicable, RBS: repetitive behaviour
scale, T2DM: type 2 diabetes mellitus.
a P value for two-way unpaired t-test, Mann-Whitney U test, or chi-squared test.
b currently receiving; note that in the PWS group, one participant was taking both an anti-depressant and an anti-psychotic; another was taking
both an anti-depressant and a benzodiazepine; and another was taking both an anti-psychotic and an anti-cholinergic.
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(Siemens MAGNETON 3T Trio), at the Wolfson Brain Imaging Centre,
University of Cambridge, Addenbrooke's Hospital, UK, using a 32-
channel head coil, with the following acquisition parameters: echo time
(TE) 2.20ms, repetition time (TR) 18.70ms, flip angle 20°, field-of-view
256mm, voxel dimensions 1.0×1.0×1.0mm.
2.2.1.2. SNORD116 microdeletion and controls. Three-dimensional,
high-resolution, T1-weighted turbo field echo brain scans collected
from 3T Philips Achieva scanner, Robert Steiner MRI Unit, MRC Clinical
Sciences Centre, Imperial College London, UK, using an 8-channel head
coil with the following acquisition parameters: echo time (TE) 4.6ms,
repetition time (TR) 9.7 ms, flip angle 8°, field-of-view 240mm, voxel
dimensions 0.94×0.94×1.2mm.
2.2.2. Neuroradiological reports
Two independent neuroradiologists reviewed all of the T1 isotropic
images in cohort 1 from 20 patients with PWS and 40 controls (M.D.
Neuroradiology Fellow; M.P. Consultant Neuroradiologist). The patient
with a SNORD116 microdeletion additionally had T2, FLAIR and
dedicated MRI pituitary images (without gadolinium contrast) re-
viewed. Both were blinded to the identity of the patients. All abnorm-
alities were documented, including previously described intracranial
defects in PWS such as ventriculomegaly, peri-sylvian polymicrogyria,
abnormal insula closure and parieto-occipital abnormalities (Manning
and Holland, 2015).
The T1 MRI brain scans of the n=95 controls in cohort 2 (for the
SNORD116 microdeletion patient) had previously been reported by a
Consultant Neuroradiologist as having no clinically significant ab-
normalities as part of routine clinical governance for our neuroimaging
research studies.
2.2.3. Brain-predicted age calculation
An overview of the methods is represented in Fig. 1. The protocol
for the brain-age prediction procedure was previously outlined in (Cole
et al., 2017b).
Acquired MRI data were preprocessed using the Statistical
Parametric Mapping (SPM12) software (University College London,
UK). The T1-weighted images underwent bias correction before being
segmented into grey matter (GM), white matter (WM) and cerebral
spinal fluid (CSF). Intracranial volume (ICV) was calculated as the sum
of GM, WM and CSF. The segmentation process was followed by a
quality check to verify the precision of the segmentation. At this stage,
images from three PWS participants had to be re-segmented, as they
failed the initial SPM segmentation. This was done using the FMRIB
Software Library Brain Extraction Tool (FSL BET) to remove extraneous
non-brain tissue from the field-of-view, after manual realignment of the
head images and resetting of the origin to the anterior commissure in
SPM. Preprocessing of the T1-weighted images ensured alignment and
corresponding voxel-wise analysis when running the machine learning
analysis. The resulting 3D maps were registered to a group-averaged
template in Montreal Neurological Institute (MNI152) using the non-
linear SPM-DARTEL algorithm and smoothed with a 4mm kernel.
Age predictions were based on the analysis of the normalized GM
and WM maps, and were generated using the Pattern Recognition for
Neuroimaging Toolbox (PRoNTo v2.0) (Schrouff et al., 2013). For each
individual, the spatially normalized maps of GM and WM were trans-
formed into vectors which were then concatenated together for each
participant. An N x N similarity matrix was obtained by calculating the
dot product of image vectors for every pair of participants. The machine
learning process used a Gaussian Processes Regression (GPR) model,
trained to predict chronological age based on structural patterns in
brain imaging data in the healthy training set (n=2001) (Cole et al.,
2015).
To validate the age prediction model, a 10-fold cross-validation was
applied to the training set, whereby the data is randomly split into 90%
for training the model and 10% for testing the model. This procedure
was repeated so that all data served as both training and testing. The
accuracy of the model was calculated as the correlation between the
real age and the predicted age, and the statistical significance of the
model was computed using a permutation test (x1000).
Once validated, the model was applied on the two testing popula-
tions (PWS and controls from cohort 1, SNORD116 microdeletion and
controls from cohort 2), 3D maps of GM and WM, to estimate the age of
the participants based on their brain structure. Brain predicted-age
difference (brain-PAD) scores were then calculated for each participant
by subtracting the real age from the predicted age. Accordingly, a po-
sitive brain-PAD value would indicate an older-appearing brain.
2.3. Statistical analysis
Statistical analysis was conducted using R v3.3.3 (www.R-project.
org) and SPSS v24, to assess normality using Kolmogorov–Smirnov test,
relationships between variables and compare experimental groups. For
brain-age prediction, brain-PAD scores were set as the dependent
variable, and co-variates for linear regression analysis included BMI, IQ,
WM and GM volumes, ICV, or behavioural measures, to study the effect
of a variable on brain-PAD within groups and between groups (PWS and
controls), reporting Pearson's correlation coefficients. Brain-PAD scores
were also regressed against chronological real age. Comparison be-
tween PWS and controls, and within groups between sexes and medi-
cation or hormone use, used two-way unpaired t-test, or Mann-Whitney
U test for data that was not normally distributed.
3. Results
3.1. Cohort description
3.1.1. Cohort 1 - PWS and matched controls
Demographics of the PWS and matched control cohort are given in
Table 1. The mean age of the two groups (PWS and controls) and the
ratio of males to females in both groups were similar (P= .73 and
P= .70 respectively). The mean IQ was significantly lower in the PWS
group (effect size mean ± SEM 49.8 ± 3.1 [95% CI 43.5, 56.1],
t=−15.9, P < .001), and the mean BMI was significantly higher in
the PWS group (effect size 6.0 ± 1.4 [3.2, 8.8], t=−4.26, P < .001).
Of the 20 participants with PWS, 17 had been treated with growth
hormone (7 of whom were still on GH at the time of the MRI scan), and
15 had been treated with sex hormones (7 of whom were still receiving
these). One of the PWS subjects had maternal UPD, while the remaining
Table 2
Characteristics of SNORD116 microdeletion patient and controls (cohort 2).
SNORD116
microdeletion
Control
n 1 95
Demographic and anthropometric data
Age (y) 24.5 34.0 ± 10.2
(19.9–55.5)
Male n (%) 1 37 (34.0%)
BMI (kg/m2) 36.9 28.7 ± 6.6 (19.1–53.1)
T2DM n (%) 1 3 (3.2%)
Medications
Growth hormone n (%) 0 0
Sex hormones n (%) 1a 0
Anti-psychotic n (%) 1a 0
Anti-convulsant n (%) 1a 0
Diabetes n (%) 1a 3 (3.2%)a
Lipid lowering medication n (%) 0 2 (2.1%)a
Anti-hypertensives n (%) 0 4 (4.2%)a
All data given as mean ± SD (range) or n (%). Abbreviations: BP: blood
pressure, T2DM: type 2 diabetes mellitus.
a Currently receiving.
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19 had a paternal chromosome 15q11–13 deletion.
3.1.2. Cohort 2 - SNORD116 microdeletion and controls
Demographics of the man with SNORD116 microdeletion and his
control comparison group are given in Table 2. He had never received
GH replacement but had received testosterone replacement from age
18 years. He was taking metformin for T2DM, and an anti-psychotic
medication (Quetiapine) and anti-convulsant medication (Carbamaze-
pine) for mood stabilization. In the control group, 3 participants were
on medications for T2DM, 2 were on lipid lowering therapy, and 4 were
on anti-hypertensive medications (Table 2).
3.2. Neuroradiological findings in PWS cohorts
In cohort 1, one out of the 20 PWS participants had dilated ven-
tricles and widened sulci, and one arrested hydrocephalus with possible
aqueduct stenosis (in total 10.0% of the PWS scans having clinically
significant abnormalities), but none of these abnormalities were seen in
the controls (Table 3). Peri-sylvian polymicrogyria, abnormal insula
closure and parieto-occipital abnormalities were not seen in any sub-
jects with PWS.
The man with a SNORD116 microdeletion had no visible abnorm-
ality on T1-, T2-weighted or FLAIR MRI brain scans or dedicated pi-
tuitary MRI scans.
3.3. Prediction of age using neuroimaging data is accurate
The chronological age of the training set was accurately predicted
by the machine learning model using the 3D T1-weighted MRI scans
(Cole et al., 2017b). The ten-fold cross-validation showed a correlation
of r=+0.94 (significant after 1000 permutations correction, P < .01)
between brain-predicted age and chronological age and explained 88%
of the variance (R2). The mean absolute error (MAE) and root mean
squared error (RMSE) of prediction were respectively 5.01 and
6.31 years. This stage validated our machine learning model as a pre-
dictor of age based on neuroimaging data for use on our test set con-
sisting of controls and PWS participants.
3.4. Individuals with PWS have higher brain-predicted age difference
Participants with PWS showed significantly higher brain-PAD scores
(mean ± SD +8.74 ± 9.14 years) than the control group
(+1.50 ± 7.42 years), with overall effect size mean ± SEM
7.24 ± 2.20 years [95% CI 2.83, 11.63], t=3.29, P= .002 (Fig. 2).
Two participants with PWS showed very high brain-PAD scores
(> +25 years). However, brain-PAD scores remained greater in PWS
than controls when excluding these subjects (effect size mean ± SEM
+5.14 ± 2.06 years [95% CI 1.02, 9.27], t=2.50, P= .015), so these
potential outliers were not driving the main group effect.
3.5. Relationship of brain-PAD with GM and WM volumes
There was no significant difference in ICV or other tissue volumes
between PWS and control groups (Table 4), and no significant overall
effect of ICV on brain-PAD when controlling for group differences
(β=−8.48 years [95% CI -25.00, 8.05], SE 8.25, P= .31, adjusted
r2= 0.17).
For GM volume, there was no significant group x GM volume in-
teraction on brain-PAD, i.e. the slopes of GM versus brain-PAD were not
significantly different between controls and PWS groups (P= .073,
Fig. 3A). Adjusting for group differences in multiple regression analysis,
there was an overall negative correlation across the 2 groups between
brain-PAD and GM volume (β=−29.17 years [95% CI -47.97,
−10.38], SE 9.39, P= .003, adjusted r2= 0.25). Adjusting for GM
volume, brain-PAD remained significantly greater in PWS than controls
(effect size mean ± SEM +6.04 ± 2.09 years [95% CI 1.86, 10.22],
t=2.90, P= .005) (Fig. 3A).
For WM volume, there was no significant group x WM volume in-
teraction on brain-PAD (P= .32, Fig. 3B). Adjusting for group differ-
ences, there was an overall positive correlation between brain-PAD and
WM volume (β=+38.04 years [95% CI 11.35, 64.74], SE 13.33,
P= .006, adjusted r2= 0.24). Adjusting for WM volume, brain-PAD
remained significantly greater in PWS than controls (effect size
mean ± SEM +7.16 ± 2.07 years [95% CI 3.01, 11.31], t=3.45,
P= .001) (Fig. 3B).
3.6. Relationship of brain-PAD with BMI, IQ, sex, behaviour and
medication use
For BMI, there was no significant group x BMI interaction on brain-
PAD (P= .54) (Fig. 3C). There was no significant correlation between
BMI and brain-PAD within either group separately (PWS: r=+0.22,
P= .35; controls r=+0.28, P= .085). When combining the groups,
adjusting for group differences, there was a trend for an overall positive
correlation between brain-PAD and BMI (β=+0.38 years [95% CI
-0.02, 0.78], SE 0.20, P= .065, adjusted r2= 0.18). However, when
adjusting for differences in BMI between groups, by including BMI in
the model, brain-PAD remained significantly greater in the PWS com-
pared to control group (effect size mean ± SEM +4.98 ± 2.46 years
[95% CI 0.04, 9.91], t=2.02, P= .048) (Fig. 3C).
Furthermore, brain-PAD also remained significantly greater in the
PWS compared to control group (effect size mean ± SEM
+5.51 ± 2.56 years [95% CI 3.44, 10.38], t=2.15 P= .037), when
matching the groups for BMI, by including only those subjects with
Fig. 1. Outline of methods for brain-age prediction using machine learning.
The data includes a training set and 2 testing sets (cohort1: controls vs. PWS; cohort 2: controls vs. SNORD116 microdeletion). The data was pre-processed using the
Statistical Parametric Mapping software (SPM). The T1 images underwent tissue segmentation after initial quality control, separating GM, WM and CSF. The
segmented images were then normalized using DARTEL for nonlinear registration, then resampled to the MNI152 template using a 4mm smoothing kernel. GM and
WM maps were concatenated into a single vector of data relating to brain size. All data underwent voxel-wise similarity analysis to generate a similarity kernel using
PRoNTo. The training set was used to generate the brain-age model via supervised machine learning that produced a Gaussian Processes Regression (GPR) model
trained to recognize structural patterns from imaging data associated with chronological age. The accuracy of the model generated from the training set was assessed
using a 10-fold cross-validation method whereby 10% of samples were used for testing in all possible iterations to generate age predictions on all samples. The trained
and validated GPR model was applied to the two test groups.
Table 3
Summary of radiological reports from T1-weighted MRI scans of PWS and
control participants (cohort 1).
Group n (%) Findings
PWS (n= 20) 18 (90.0%) Normal scan
1 (5.0%) Dilated ventricles and widened sulci
1 (5.0%) Arrested hydrocephalus, possible aqueduct
stenosis
Control (n= 40) 34 (85.0%) Normal scan
2 (5.0%) Developmental venous anomaly
4 (10.0%) Other benign findingsa
a Other findings include small low signal lesion in right genu (possible in-
cidental neuroepithelial cyst), maxillary sinus mucus, mega cisterna magna,
small lipoma/dermoid in infundibular recess. None of the findings met exclu-
sion criteria.
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PWS having BMI<34.2 kg/m2, the maximum BMI in the control group
(n=15, BMI median 26.7 [IQR 24.0, 30.0], range 21.5–33.7, 80.0%
male), and controls with BMI> 21.5 kg/m2, the minimum BMI in the
PWS group (n=29, BMI median 24.6 [23.3, 27.1], 21.7–34.2, 62.1%
male; BMI PWS vs. control: Z -1.02, P= .31).
For IQ, there was with no significant group x IQ interaction on
brain-PAD (P= .12) (Fig. 3D). There was no significant correlation
between IQ score and brain-PAD within either group separately (PWS:
r=+0.22, P= .35; controls r=−0.20, P= .22), or when combining
groups with adjustment for group differences (β=−0.03 years [95%
CI -0.21, 0.16], SE 0.09, P= .79, adjusted r2= 0.13) (Fig. 3D).
There was no significant sex difference in brain-PAD in either group
(PWS: male effect size mean ± SEM -6.63 ± 4.31 years [95% CI
-15.68, 2.42], t=−1.54, P= .14; controls: male effect size
3.11 ± 2.44 years [95% CI -1.83, 8.05], t=1.28, P= .21), or in the
whole cohort, adjusting for group differences (male effect size
−0.04 ± 2.22 years [95% CI -4.48, 4.41], t=−0.02, P= .99, ad-
justed r2= 0.13).
In the PWS group, there was no significant correlation between
brain-PAD and either repetitive behaviour using RBS-R sameness score
(r=+0.26, P= .26), or disruptive behaviour using DPC-A disruptive
score (r=+0.21, P= .21).
In the PWS group, there was also no significant effect on brain-PAD
of medication use, for growth hormone (past or current use: t=0.81,
P= .43; current use: t=0.57, P= .58) or sex hormones (past or cur-
rent use: t=−0.47, P= .65; current use: t=0.17, P= .87), or current
use of any psychoactive medication (t=0.42, P= .68), anti-psychotics
(t=0.20, P= .84) or anti-depressants (t=−0.34, P= .74).
3.7. SNORD116 microdeletion is associated with high brain-PAD score
The man with PWS due to a SNORD116 microdeletion had a brain
age of 37.36 years compared to an actual chronological age of
24.49 years (Fig. 4A). The resulting brain-PAD score for this patient was
+12.87 years, appeared markedly higher than the average brain-PAD
of the respective control group (mean ± SD +0.84 ± 6.48 years),
including when adjusting for chronological age (Fig. 4B) or BMI
(Fig. 4C).
4. Discussion
Individuals with PWS had a brain age that more closely resembled
healthy adults on average 8.74 years older than their chronological age.
This effect was evident relative to age and scanner-matched typically
developing controls, in whom no such increase was observed. The
findings were independent from lifetime or current receipt of growth
hormone or sex hormones, and current use of psychotropic medications.
Increased brain age in PWS was also independent of WM and GM tissue
volumes, which were not significantly different between groups, and
was also independent of the higher BMI in the PWS than control group.
85% of the brain-PAD scores in the PWS scores were positive (17/
20), which means that most of PWS individuals in our study showed an
increased predicted brain age. However, any variability in brain-PAD
scores in the PWS group could not be explained by medication use,
including growth or sex hormones or psychotropic drugs, sex or current
BMI. In addition to normal individual variation, potential factors might
be duration or timing of hormonal replacement, duration or dosage of
psychotropic medication, age of onset and duration of obesity, or me-
tabolic complications of obesity. Greater brain age has been associated
with poor health outcomes, so the variability might become more re-
levant with longitudinal follow-up.
Fig. 2. Brain-predicted age in individuals with
Prader-Willi syndrome (PWS) and controls (cohort
1).
(A,B) Scatterplot of (A) brain-predicted age or (B)
brain-predicted age difference (brain-PAD) (y-axis)
vs. chronological real age (x-axis) in controls (blue
triangles, blue dashed linear regression line) and
individuals with PWS (red circles, red solid linear
regression line), with line of identity (black dotted
line). (C) Boxplot shows brain-PAD scores distribu-
tion with median, interquartile range, and bars
showing 5th and 95th percentiles, with outliers as
symbols, and mean as a cross. (For interpretation of
the references to color in this figure legend, the
reader is referred to the web version of this article.)
Table 4
Brain tissue volumes in PWS and control groups (cohort 1).
PWS Control P-value
WM volume (cm3) 0.480 ± 0.083 0.478 ± 0.070 0.92
GM volume (cm3) 0.662 ± 0.106 0.703 ± 0.104 0.16
CSF volume (cm3) 0.233 [0.198, 0.278] 0.238 [0.187, 0.317] 0.82a
ICV (cm3) 1.396 [1.308, 1.473] 1.430 [1.312, 1.545] 0.16a
Data given as mean ± SD, or median [interquartile range], in cm3 for white
matter (WM), grey matter (GM), cerebrospinal fluid (CSF) volumes and total
intracranial volume (ICV), with P-values for differences in between groups by 2-
way unpaired t-test or a Mann-Whitney U test.
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Participants with PWS showed signs of premature brain aging and
early onset atrophy rather than a fundamental arrest of brain devel-
opment. Patterns of brain structure more closely resembled healthy
older brains rather than healthy younger brains, which might be in-
dicative of premature neuronal loss and atrophy. Even slight decrease
in brain tissue volumes might be picked up by the trained model as a
biomarker of aging as it has already been established that there is a
widespread reduction of GM and WM volumes from young adulthood
and onwards (Giorgio et al., 2010).
Previous studies using food intake or food cue related paradigms
have revealed functional neuroimaging abnormalities in PWS, focusing
mainly on subcortical and cortical structures usually involved in eating
behaviour, reward and motivation (Manning and Holland, 2015).
However, reports of structural brain abnormalities in PWS have in-
cluded: ventriculomegaly and cortical abnormalities such as atrophy or
abnormal gyrification (Hayashi et al., 1992; Hashimoto et al., 1998;
Yoshii et al., 2002; Miller et al., 2007), reduction in total brain volumes
or brainstem volume (Miller et al., 2009; Ogura et al., 2011; Lukoshe
et al., 2013); and irregularity or malformation of the thalamus, pitui-
tary gland, corpus callosum, insula and sylvian fissure (Leonard et al.,
1993; Iughetti et al., 2008; Gilboa and Gross-Tsur, 2013). In the current
study, 90% of PWS participants had a normal T1-weighted scan, 1/20
participants had ventriculomegaly and 1/20 participants had arrested
hydrocephalus and possible aqueduct stenosis. However, we did not
detect any of the other abnormalities reported above, and so were able
to distinguish such structural abnormalities from premature brain aging
using a quantitative assessment of brain development rather than
multiple measures of independent structures and categorization. Ana-
lysing widespread structural differences in a cross-sectional population-
based study enhances the generalizability of the findings in comparison
to the case reports of neuroimaging abnormalities in PWS while
studying the brain as a whole.
Interestingly, the higher brain age in PWS was not related to
changes in GM and WM volumes which did not differ between controls
and PWS groups, emphasizing the strengths of brain age over standard
structural volumetrics, as the patterns picked up by the model are
Fig. 3. Brain-predicted age difference in individuals
with Prader-Willi syndrome (PWS) and controls
(cohort 1).
Scatterplot of brain-predicted age difference (brain-
PAD) (y-axis) vs. (A) GM volumes, (B) WM volumes,
(C) BMI, or (D) IQ (x-axis), in individuals with PWS
(red circles, red solid linear regression line) and
controls (blue triangles, blue dashed linear regres-
sion line). (For interpretation of the references to
color in this figure legend, the reader is referred to
the web version of this article.)
Fig. 4. Brain-age prediction in man with SNORD116 microdeletion and controls (cohort 2).
Male with a SNORD116 micodeletion (red filled circle) shows an increase in (A) brain age, and (B,C) brain-PAD scores when adjusting for (B) chronological real age
or (C) BMI, compared to the control group (unfilled blue circles, and in (A) solid blue regression line). Black dotted line is line of equality (For interpretation of the
references to color in this figure legend, the reader is referred to the web version of this article.).
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spatially distributed. Indeed, more localised examination of structural
brain differences in PWS using voxel-based morphometry from the
same cohort as in this study, has revealed increased volume in the
prefrontal cortex, especially medially, the majority of the cingulate
cortices, insula cortices, and areas of the parietal and temporal cortices,
caudate, putamen and thalamus, with increased cortical volume largely
driven by greater cortical thickness. Reduced volume was found in
ventromedial prefrontal areas, medial temporal lobe, bilateral temporal
poles, and right lateral prefrontal cortex, while myelination of the
cortex was broadly unchanged, with the exception of some highly lo-
calised areas, including the insula (Manning et al., 2018).
Our current findings contrast with a previous study reporting that
children with PWS showed a fundamentally arrested brain development
(Lukoshe et al., 2013). This was especially seen in young children with
a chromosome 15q11–13 deletion as compared to children with the
maternal UPD genotype. The current study consisted predominantly of
patients with the deletion genotype, but did not rely on simply mor-
phological measures determined from the Freesurfer software as in the
previous study, but used a whole-brain method based on reference to a
model of healthy brain aging defined in an independent sample. Fur-
thermore, our cohort consisted of young adults with PWS rather than
children. These differences in methodology and demographics might
explain the contrast of results and possibly reveals changes in structural
patterns associated with different stages of neurodevelopment.
Although our study is not the first to examine brain structure in
young adults with PWS, it is the first to use a pre-defined model of the
structural pattern of the brain in healthy adults to compare structural
abnormalities in PWS. Moreover, our analysis has an emphasis on
markers of aging, known to be associated with a higher risk of death,
poorer cognitive function and impaired physical fitness (Cole et al.,
2018). The use of a large training set and a well-validated model further
confirm the accuracy of the result and draws a clear difference between
typical aging and aging in PWS.
It is important to acknowledge the limitations and strengths of our
techniques. First and foremost, the sample size of our PWS group is
relatively small (n=20), but this is usual in studies of PWS because of
the rarity of the disease and the difficulty of recruitment and scanning.
Scans from different sources were used for the large training set, for
which detailed demographic data were not available. However, it was
verified that individuals were free from neurological, psychiatric or
mental diseases before using the scans to train the model, and the large
number of data used (n=2001) puts the brain-PAD scores of the PWS
group in appropriate context. The limited age range of our cohort (both
PWS and controls) is both a strength and a constraint, since it elim-
inates the confounding effect of age, but it may restrict generalizations
of the results to other age groups. Therefore, there is still a possibility
that brain-PAD scores in subjects with PWS under 18 years of age might
be reduced.
In addition, our analysis was cross-sectional, and without further
longitudinal studies, the relationship between brain-predicted age,
neurological phenotypes and complications, or mortality risk, in asso-
ciation with age, cannot be determined, especially in a cohort with a
mean age of 23 years. Cross-sectional studies can only suggest pre-
mature brain aging. Given that the control group was recruited at the
University of Cambridge, participants might have been exposed to po-
sitive influences on apparent brain age, which is further emphasized by
the above-average IQ test scores in the control group.
Brain development in utero might already be impaired in PWS pa-
tients. Phase 0 of the 4 nutritional phases occurs in utero, during which
the foetus shows signs of decreased movements (prenatal hypotonia)
and growth restriction (Cassidy et al., 2012; Miller et al., 2011).
Moreover, some effects of the loss of function of genes involved in PWS
may also be expressed prenatally e.g. they may be confined to the
placenta (Robinson et al., 1997). The timing and the nature of birth also
seems to influence development in PWS. The position of the foetus at
the onset of labor is often abnormal, and a high percentage of children
are born either pre- or post-maturely (Swaab, 1997). Premature birth
impacts brain structure and development in general, with loss of the
neurogenesis stage which is usually still present throughout the third
trimester (Malik et al., 2013). Newborns with PWS have a lower BMI
than healthy siblings by 15–20% (Miller et al., 2011), indicating early,
prenatal, abnormal development. The failure-to-thrive at younger age
seems to begin in utero, given that the imprinted genes in PWS are
already absent prenatally (Butler et al., 2009). Early work on imprinted
genes showed their importance on growth in general, and on neuro-
development, brain size and organization (Wilkinson et al., 2007). The
largest proportion of the discovered imprinted genes in the PWS chro-
mosomal region are expressed, though not exclusively, in the brain, and
are key in early brain development. Findings of increased cortical
thickness and reduced gyrification in PWS are consistent with dis-
turbances in neuronal migration during foetal cortical development
(Lukoshe et al., 2013; Manning et al., 2018).
The complex genetic background of PWS, together with the com-
plicated role of the genes involved in the syndrome might explain some
the neurodevelopmental deficits driving our results, as well as the large
variability in brain-PAD scores. The exact function and relative im-
portance of each of the genes involved in PWS still needs to be further
elucidated, although it is clear that some rare genes are key to the
development of the central nervous system in early stages, or in later
stages, thus promoting early atrophy.
As an example, some studies have shown that several paternally
expressed genes found in the PWS region of mice models are necessary
for cortical development. One of the genes, Necdin (Ndn), is a neuronal
cell cycle regulator, usually upregulated during development, differ-
entiation and migration of neuronal cells. Ndn mutant mice have ab-
normal neuronal migration and cortical development (Pagliardini et al.,
2005). Another gene whose expression is lost in PWS is Magel2, im-
portant for pre- and post-natal development specifically of the hy-
pothalamus (Lee et al., 2003). The deficits associated with the loss of
function of Magel2 might worsen with age, due to the lack of clearance
of ubiquitinated proteins from the cells (Pravdivyi et al., 2015), which
could contribute to neuroinflammation and activation of stress path-
ways. A recent report of gene expression in post-mortem hypothalamic
tissue in PWS reported a transcriptomic profile similar to that seen in
neurodegenerative conditions and the aging brain, with downregulated
genes mainly found in neuronal cells and involved in neurogenesis and
synaptic plasticity, while upregulated genes were mainly microglial and
associated with inflammatory responses (Bochukova et al., 2018). In
addition, a recent small study found decreased ex vivo mitochondrial
function in fibroblast cell lines from patients with PWS (especially in
those with deletion genotype) that might also play a pathogenic role in
accelerated brain aging if also seen in other cell types (Butler et al.,
2018).
Study of rare mutations or microdeletions of specific genes can also
reveal much about genotype-phenotype association. A strength of the
brain age study design is that individualised predictions can be made,
allowing comparison of single subjects to a model of normal brain
aging. We also examined the brain-PAD score of a 24.5 years old male
with a genetically confirmed 187 kb microdeletion at chromosome
15q11–13 (de Smith et al., 2009). He had an advanced brain-PAD of
+12.87 years, compared to a separate set of control adults (that ap-
peared independent of chronological age and BMI). This patient dis-
plays hyperphagia, obesity, hypogonadism and other features com-
monly associated with PWS. This microdeletion encompasses a family
of paternally expressed, maternally imprinted, non-coding RNAs, par-
ticularly the SNORD116 small nucleolar RNA (snoRNA) cluster. Given
that this patient exhibits a similar increase in brain-PAD score within
the range of brain-PAD scores of our PWS cohort, we hypothesize that
the loss of function for this genetic cluster might be sufficient to cause
premature brain aging. Two studies on mice lacking the snord116 gene
cluster showed growth and motor learning deficiencies, and a possible
hyperphagic phenotype (Ding et al., 2008; Qi et al., 2016), although
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more work is needed to understand the impact of the snoRNAs on brain
structure and development.
Some genotype-phenotypes associations between different genetic
subtypes resulting in PWS, have been described, such as differences in
autistic features, risk of psychosis in adulthood, and differential brain
development (Mitchell et al., 1996; Boer et al., 2002; Soni et al., 2008;
Sinnema et al., 2011; Lukoshe et al., 2013). It should be noted that the
vast majority of subjects in the current study had a paternal chromo-
some 15q11–13 deletion, with only 1 out of 20 having mUPD. However,
this subject with mUPD had a brain-age score well within the range of
the PWS group with a deletion.
Aside from the varying genetic background that might be a cause for
the atypical brain development, PWS is also the most common genetic
syndromal cause of morbid obesity. Evidence points at an increase in
oxidative stress associated with both obesity and aging (Furukawa
et al., 2004), with a higher production of pro-inflammatory cytokines
interacting with the brain (Chung et al., 2009; Arnoldussen et al.,
2014). Interleukin-6 and tumor-necrosis factor, found in both the per-
iphery (produced by fat cells) and the brain (produced by neurons,
astrocytes and microglia), which normally contribute to neurogenesis,
neuroinflammation and synaptic plasticity, seem to be linked to cog-
nitive decline, neurodegeneration and brain atrophy in obese people
(Wilson et al., 2002; Griffin, 2006), as well as increased risk of de-
mentia and Alzheimer's disease (Gustafson et al., 2004; Whitmer et al.,
2005). Moreover, leptin, a hormone produced by adipose tissue, seems
to be related to inflammatory response in microglia, with a positive
feedback loop for sustained cytokine production, which are in turn
associated with WM changes (Wisse, 2004; Bolzenius et al., 2013;
Kullmann et al., 2015). However, there is no evidence of different leptin
concentrations in the serum of PWS individuals (Goldstone et al.,
2002), but evidence suggests activation of the innate immune system
independently of hormonal imbalance in obesity (Viardot et al., 2010).
In PWS, all of these factors might lead to differential brain development
and aging depending on the age and the genetic predisposition of the
patients.
Previous structural neuroimaging studies have shown that BMI is
associated with decreased volume of the limbic and frontal GM regions
in healthy children (Alosco et al., 2014) and widespread brain regions
in adults (Cole et al., 2013). These changes are in turn related to cog-
nitive decline and other neurocognitive outcomes (Gunstad et al.,
2008). A recent study also showed that WM volume in overweight and
obese people was associated with premature cortical atrophy and an
increased brain age of 10 years from middle age, with differential ef-
fects depending on brain tissue types (Ronan et al., 2016). There is also
evidence that BMI is associated with global decrease of WM micro-
structural integrity (Verstynen et al., 2012). In the current study, there
was an overall trend across combined control and PWS groups for
higher BMI to be associated with a higher brain-PAD, with each 1 kg/
m2 increase in BMI advancing brain-PAD by +0.38 years. However, the
higher brain-PAD in PWS than controls was not explained by the higher
BMI in PWS, since it persisted when adjusting for BMI, and when re-
stricting analysis to a sub-cohort matched for BMI. It remains possible
that with even more extreme obesity in PWS that there is an interaction
between the effects of PWS, obesity and its metabolic complications, on
accelerating brain aging. Unfortunately, no questionnaire or beha-
vioural measurements of hyperphagia were available in the PWS group,
to examine any bidirectional association between brain aging and
overeating behaviour in PWS, independent of BMI. This would be useful
to examine in future studies. Furthermore, the small sample size may
have caused a type 2 error in any influence of sex on brain-PAD, as
there was a trend for brain-PAD to be lower in men than women with
PWS, though the PWS group was also predominantly male.
In future investigations of PWS, the use of a larger age range,
especially including children and adolescents, individuals with more
severe obesity, and a longitudinal study would help uncover the natural
history of brain development and aging and the interaction with
development of obesity. Understanding how brain aging differs be-
tween the different genotypes (especially mUPD (or imprinting centre
microdeletions and imprinting defects) vs. paternal deletion, type I vs
type II deletions, and rarer microdeletions involving snoRNA clusters,
and specific gene mutations e.g. MAGEL2, MKRN3 genes) would also
help understand the role of specific genes in the PWS regions, potential
mechanisms leading to premature aging in PWS, role for gene dosage
outside of the PWS critical region, and the potential neurobiological
basis of genotype-phenotype interactions in PWS, for example the in-
creased risk of psychosis with mUPD. Given the widespread neurolo-
gical effects of PWS, it will be especially helpful to incorporate different
imaging and analysis techniques such as DTI and structural and func-
tional MRI and multi-modality brain-age prediction in the study of
older patients with PWS.
Further understanding of the potential role of obesity and associated
metabolic factors, and PWS genotypes, in the development of increased
brain aging in PWS will emphasize additional reasons to develop stra-
tegies and novel therapies to prevent and treat overeating, weight gain
and metabolic syndrome, and perhaps even targeted to particular
genotypes. Furthermore, as adults live longer with PWS with earlier
diagnosis and improved multi-disciplinary care, including the use of
specialist residential placements, the presence of accelerated brain
aging identified through MRI brain scans, may identify individuals at
risk of cognitive decline in later adulthood, perhaps through neurode-
generative pathological processes leading to dementia, who may need
closer monitoring, aggressive treatment of reversible risk factors and
perhaps early use of pharmacological therapies (Sinnema et al., 2010;
Sinnema et al., 2012; Whittington et al., 2015).
In conclusion, this neuroimaging study indicates that PWS is asso-
ciated with an increased brain-age from early adulthood. This conclu-
sion challenges the competing hypotheses (arrested development vs.
premature aging) trying to explain structural brain abnormalities in
PWS. This approach suggests that there may be neurological implica-
tions of the syndrome in older age, which may have important clinical
implications as the life expectancy of patients with PWS is prolonged
with better management of the food environment and avoidance of
obesity-related complications.
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